16 July 2018

Circassia Pharmaceuticals plc

Result of General Meeting

Further to the announcement made on 27 June 2018 by Circassia Pharmaceuticals plc ('Circassia' or 'the Company') (LSE: CIR) regarding the publication of a Circular containing a Notice of General Meeting of the Company's shareholders, the Company announces that the Special Resolution contained in the Circular was duly passed at a general meeting of the Company held today. The result of the poll in relation to the Special Resolution was as follows:

Special Resolution

For

%

Against

%

Withheld*

To:

(i) approve the related-party transaction with AstraZeneca and implement the terms of the Amendment Letter and give effect to the proposed amendments to the DCA;

(ii) issue and allot Ordinary Shares up to an aggregate nominal amount of £18,980.64; and

(iii) disapply the pre-emption rights that would otherwise apply in respect of the issuance and allotment of Ordinary Shares to AstraZeneca in connection with the Transaction

233,507,567

100.0

2,839

0.0

5,673

* A vote withheld is not a vote in law and is not counted in the calculation of the votes 'For' or 'Against' a resolution.

As such, an application has been made to the UK Listing Authority and the London Stock Exchange for 23,725,800 ordinary shares of 0.08 pence each in the Company ('Ordinary Shares') to be admitted to the premium listing segment of the Official List of the UK Listing Authority and to trading on the London Stock Exchange's main market for listed securities (together, 'Admission'). It is expected that Admission will become effective at 08:00 a.m. on 17 July 2018. When issued, the Ordinary Shares will rank pari passuwith the existing Ordinary Shares of the Company.

Capitalised terms herein shall have the definitions given to them in the Circular dated 27 June 2018 (the 'Circular') unless where otherwise stated. The full text of the resolution is shown in the Notice of General Meeting set out in the Circular.

In accordance with LR 9.6.2, a copy of the resolutions passed at today's General Meeting will be submitted to the National Storage Mechanism and will be shortly available for inspection atwww.morningstar.co.uk/uk/NSM.

A copy of this announcement will be posted on the company's website, www.circassia.com.

For further information, please contact:

Circassia Pharmaceuticals plc

Julien Cotta, Company Secretary +44 (0) 1865 405560

Attachments

  • Original document
  • Permalink

Disclaimer

Circassia Pharmaceuticals plc published this content on 16 July 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 16 July 2018 14:35:03 UTC